Question

哪位医学英语高手帮我翻译一下医学论文的摘要

26: Lancet. 2008 Feb 23;371(9613):651-9. Epub 2008 Feb 14.
Related Articles, Links

Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.

Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG; Dutch Acute Pancreatitis Study Group.

Department of Surgery, University Medical Center Utrecht, Utrecht, Netherlands.

BACKGROUND: Infectious complications and associated mortality are a major concern in acute pancreatitis. Enteral administration of probiotics could prevent infectious complications, but convincing evidence is scarce. Our aim was to assess the effects of probiotic prophylaxis in patients with predicted severe acute pancreatitis. METHODS: In this multicentre randomised, double-blind, placebo-controlled trial, 298 patients with predicted severe acute pancreatitis (Acute Physiology and Chronic Health Evaluation [APACHE II] score > or =8, Imrie score > or =3, or C-reactive protein >150 mg/L) were randomly assigned within 72 h of onset of symptoms to receive a multispecies probiotic preparation (n=153) or placebo (n=145), administered enterally twice daily for 28 days. The primary endpoint was the composite of infectious complications--ie, infected pancreatic necrosis, bacteraemia, pneumonia, urosepsis, or infected ascites--during admission and 90-day follow-up. Analyses were by intention to treat. This study is registered, number ISRCTN38327949. FINDINGS: One person in each group was excluded from analyses because of incorrect diagnoses of pancreatitis; thus, 152 individuals in the probiotics group and 144 in the placebo group were analysed. Groups were much the same at baseline in terms of patients' characteristics and disease severity. Infectious complications occurred in 46 (30%) patients in the probiotics group and 41 (28%) of those in the placebo group (relative risk 1.06, 95% CI 0.75-1.51). 24 (16%) patients in the probiotics group died, compared with nine (6%) in the placebo group (relative risk 2.53, 95% CI 1.22-5.25). Nine patients in the probiotics group developed bowel ischaemia (eight with fatal outcome), compared with none in the placebo group (p=0.004). INTERPRETATION: In patients with predicted severe acute pancreatitis, probiotic prophylaxis with this combination of probiotic strains did not reduce the risk of infectious complications and was associated with an increased risk of mortality. Probiotic prophylaxis should therefore not be administered in this category of patients.

Publication Types:
• Research Support, Non-U.S. Gov't

PMID: 18279948 [PubMed - in process]

Answer 1

2008年2月26日:《柳叶刀》上。9613;371(23):651 - 9。Epub 2008年2月14日。 相关的文章,连接 益生菌治疗急性重症胰腺炎预测:随机、双盲、安慰剂对照试验。 Besselink毫克,范Santvoort HC,Buskens E,Boermeester马、货车Goor H,Timmerman HM,Nieuwenhuijs VB组合成的TL型、货车、营运Ramshorst B,Witteman Rosman 1061 Ploeg刃具、边缘,马,Schaapherder房颤、Dejong CH,Wahab PJ,范Laarhoven CJ,安迪·Eijck Harst E,麻萨诸塞州,Akkermans廖建忠、Cuesta汞、荷兰、Gooszen激光束急性胰腺炎研究小组。 部门,大学医学中心外科手术、乌得勒支、荷兰乌。背景:感染性并发症及相关的死亡率是急性胰腺炎关注的主要问题。肠道益生菌可以防止传染病管理的并发症,但是令人信服的证据是很少的。我们的目的是评估摄服益生菌的影响患者的预防性治疗急性重症胰腺炎的预测。方法:在此multicentre随机、双盲、安慰剂对照试验,预测298例重症胰腺炎(急性生理学和慢性健康评价[鞍鞯II)得分,Imrie > = 8 >或3位,得分或c反应蛋白> 1.5毫克/升)被随机分配在72小时出现症状获得multispecies益生菌准备(n = 153)或安慰剂(n = 145页),为28天每天两次伤。主要终末点是综合的感染性并发症——即感染肺炎菌血症、坏死、胰腺癌、urosepsis或感染腹水——在入学和90天的随访。分析了治疗意图。本研究ISRCTN38327949登记、数量。结果:每组中有一个人被排除,因为不正确的诊断分析152人;因此,胰腺炎的益生菌集团和144安慰剂对照组进行统计分析。团体一样的基线而言,病人的特点和疾病的严重性。感染性并发症发生在46(30%)患者的益生菌集团和41%的人(28%)在安慰剂组(相对危险度1.06,95%可信区间为0.75 -试验),24(16%)的患者相比,益生菌组死亡9例(6%),对照组(相对危险度股票,95%可信区间为122 - 5.25)。9名患者中肠缺血(益生菌集团开发与致命的后果)8,与之相比,在安慰剂组比较差异有统计学意义(p = 0.004).差异。 解释:在预测急性重症胰腺炎患者预防与该组合,益生菌对益生菌菌株没有降低患感染性并发症及相关的风险增加死亡率。益生菌预防不应给予这类的病人。